547,599 Shares in ADMA Biologics Inc $ADMA Bought by Legal & General Group Plc

Legal & General Group Plc bought a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 547,599 shares of the biotechnology company’s stock, valued at approximately $4,583,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of ADMA Biologics in the second quarter worth about $321,037,000. Janus Henderson Group PLC lifted its holdings in shares of ADMA Biologics by 3,906.1% during the 4th quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company’s stock valued at $71,820,000 after purchasing an additional 3,838,158 shares in the last quarter. Capital Research Global Investors grew its position in shares of ADMA Biologics by 104.0% in the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after purchasing an additional 3,383,559 shares during the period. Caligan Partners LP acquired a new position in shares of ADMA Biologics in the 3rd quarter valued at approximately $38,653,000. Finally, Sachem Head Capital Management LP increased its stake in ADMA Biologics by 27.0% during the 4th quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock worth $207,480,000 after purchasing an additional 2,415,000 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Zacks Research lowered shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 4th. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a report on Thursday, June 18th. Mizuho cut their price objective on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Canaccord Genuity Group reduced their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Raymond James Financial began coverage on ADMA Biologics in a report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 target price for the company. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $18.67.

ADMA Biologics Stock Performance

Shares of ADMA opened at $9.58 on Friday. The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of 13.69 and a beta of 0.78. ADMA Biologics Inc has a 12 month low of $7.21 and a 12 month high of $20.46. The firm has a fifty day simple moving average of $9.13 and a 200 day simple moving average of $10.31. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The firm had revenue of $124.39 million for the quarter, compared to analyst estimates of $125.34 million. During the same period in the previous year, the business earned $0.14 EPS. The company’s revenue was up 2.0% compared to the same quarter last year. Research analysts forecast that ADMA Biologics Inc will post 0.78 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.